Shattuck Labs, Inc. STTK 深 滬
等待開盤 08-06 09:30:00 美东时间
0.99
+0.247
+33.30%
華盛通- 最 高1.15
- 今 開1.00
- 成交量 9415.24万股
- 最 低 0.9133
- 昨 收 0.7427
- 總市值 4742.42万
- 52周最高 3.95
- 市盈率 靜 --
- 換手率 196.55%
- 52周最低 0.6922
- 委 比 -68.50%
- 總股本 4790.32万
- 歷史最高 60.516
- 量 比 1788.00
- 振 幅 31.87%
- 歷史最低 0.6922
- 每 手 1
- 風險率 0.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Y-mAbs Therapeutics (NASDAQ:YMAB) stock rose 103.2% to $8.52 during Tu...
今天 01:06
Shattuck Labs Secures Up To $103M In Private Placement Financing Through Securities Purchase Agreement
– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease –– Pro forma cash and cash equivalents
08-05 18:37
Shattuck Labs Elects Directors, Approves Auditor at Meeting
The latest update is out from Shattuck Labs ( ($STTK) ). On July 10, 2025, Shat...
07-16 04:57
Shattuck Labs Management To Participate In DR3/TL1A Focused Panel Discussion And In One-On-One Meetings At Leerink Partners Therapeutics Forum: I&I And Metabolism
Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with
07-02 19:13
Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism
Shattuck Labs, a biotech公司，宣布其管理层将参加7月8日至9日在波士顿举行的 Leerink Partners 论坛，参与DR3/TL1A主题的小组讨论及一对一会议。公司重点开发 SL-325，这是一种潜在的同类首创新药，通过阻断DR3受体靶向DR3/TL1A通路，用于治疗炎症性肠病及其他炎症性疾病。目前，SL-325已完成非人灵长类的GLP毒理学研究，计划于2025年第三季度提交IND申请。
07-02 11:00
Shattuck Labs Advances SL-325 Program Amid Financial Progress
Shattuck Labs, Inc. ( ($STTK) ) has released its Q1 earnings. Here is a breakdo...
05-06 12:05
Why Levi Strauss Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Shares of Levi Strauss & Co. (NYSE:LEVI) rose sharply in today's pre-market...
04-08 17:02
Shattuck Labs GAAP EPS of -$0.37
Shattuck Labs press release (NASDAQ:STTK): Q4 GAAP EPS of -$0.37. As of December 31, 2024, cash and cash equivalents and investments were approximately $73.0 million, as compared to $130.6 million as ...
04-02 22:43
Needham Reiterates Hold on Shattuck Labsto Hold
Needham analyst Gil Blum reiterates Shattuck Labs (NASDAQ:STTK) from Hold to Hold.
03-28 01:23
美股大行评级 | 花旗：维持爱科集团"中性"评级，目标价从95美元升至98美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1108674722736648193.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Aemetis(AMTX)"买入"评级，目标价从18美元升至19美元</p> <p>• Ascendiant Capital：维持Daxor Corp.(DXR)"买入"评级，目标
03-18 10:15
